Combination of indomethacin and statin compared with indomethacin and placebo in patients with first episode of acute pericarditis: preliminary findings
Résumé
The aim of the study was to evaluate the safety and efficacy of the combination of indomethacin and statin versus indomethacin plus placebo in patients with a first episode of pericarditis. Fifty five consecutive patients with acute pericarditis were randomized in double blind fashion into two groups: group 1 was treated with indomethacin 150 mg plus rosuvastatin 10 mg and group 2 was treated with indomethacin 150 mg plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments (WCc, ESR, CRP, TNI, CK/MB, BNP plasma levels) and ECG and echocardiogram were performed at baseline and daily up to discharge. All the patients were followed as outpatients for 3 months to evaluate a recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters. Group 1 (the statin group) included 28 patients, 18 M/10 F, age 29.5±5.7 years; group 2 (placebo group) comprised 27 patients 16 M/11 F, age 29.2±4.8 years. The statin group showed a significant faster reduction in CRP values (5.0±1 vs 6.0±2 days, p=0.022), in ST segment normalization (3.5±1 vs 4.5±1 days, p=0.001), pericardial effusion (4.5±1 vs 5.5±1 days, p=0.001) and ESR (5..0±1 vs 6.0±2, p=0.022). Our data show that the combination of statin and indomethacin in patients with acute pericarditis is feasible, showing a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2 vs 6.5±2,p=0.069). These preliminary findings require further studies on a larger patient sample.
Origine : Fichiers produits par l'(les) auteur(s)